- Home
- CNFR vs IBIO Comparison
CNFR vs IBIO Comparison
Compare CNFR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- IBIO
- Stock Information
- Founded
- CNFR 2009
- IBIO 2008
- Country
- CNFR United States
- IBIO United States
- Employees
- CNFR N/A
- IBIO N/A
- Industry
- CNFR Property-Casualty Insurers
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CNFR Finance
- IBIO Health Care
- Exchange
- CNFR Nasdaq
- IBIO Nasdaq
- Market Cap
- CNFR 7.9M
- IBIO 9.3M
- IPO Year
- CNFR 2015
- IBIO N/A
- Fundamental
- Price
- CNFR $0.82
- IBIO $0.73
- Analyst Decision
- CNFR
- IBIO Strong Buy
- Analyst Count
- CNFR 0
- IBIO 3
- Target Price
- CNFR N/A
- IBIO $4.87
- AVG Volume (30 Days)
- CNFR 35.6K
- IBIO 2.3M
- Earning Date
- CNFR 05-14-2025
- IBIO 05-02-2025
- Dividend Yield
- CNFR N/A
- IBIO N/A
- EPS Growth
- CNFR N/A
- IBIO N/A
- EPS
- CNFR 1.92
- IBIO N/A
- Revenue
- CNFR $66,771,000.00
- IBIO $375,000.00
- Revenue This Year
- CNFR $25.91
- IBIO $36.00
- Revenue Next Year
- CNFR N/A
- IBIO N/A
- P/E Ratio
- CNFR $0.43
- IBIO N/A
- Revenue Growth
- CNFR N/A
- IBIO 650.00
- 52 Week Low
- CNFR $0.42
- IBIO $0.64
- 52 Week High
- CNFR $1.91
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- CNFR 64.23
- IBIO 24.07
- Support Level
- CNFR $0.70
- IBIO $0.75
- Resistance Level
- CNFR $0.86
- IBIO $0.82
- Average True Range (ATR)
- CNFR 0.06
- IBIO 0.14
- MACD
- CNFR 0.02
- IBIO 0.10
- Stochastic Oscillator
- CNFR 83.22
- IBIO 3.04
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.